Fulvestrant vs Tamoxifen (Soltamox)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Fulvestrant · Faslodex
Marketed by AstraZeneca
NCT00635713 · Phase 3 · completed
The trial randomized an estimated 588 participants and used double blinding to compare two active treatment groups: fulvestrant 125 mg plus anastrozole versus fulvestrant 250 mg plus anastrozole. Its primary endpoint was time to tumor progression, a clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
ClinicalTrials.gov records both arms as fulvestrant plus anastrozole. The published North American Trial 0021 (Osborne 2002) randomized fulvestrant 250 mg monthly against anastrozole 1 mg daily, double-blind and double-dummy.
Next expected readout: December 2026 · NCT07163481 (registry estimate)
Reported efficacy
Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59) (met)
Result source: NCT01602380
Tamoxifen (Soltamox)
Marketed by Mayne Pharma and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04174352 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Fulvestrant | Tamoxifen (Soltamox) |
|---|---|---|
| PFS, median | 4.7 vs 3.8+0.9 vs placeboNCT0039045517 other results
| 20.2 vs 15.6vs Endocrine TherapyNCT006019002 other results
|
| OS, median | 29.9 vs 26.4+3.5 vs placeboNCT0039045510 other results
| 47.2 vs 43.9vs Endocrine TherapyNCT006019001 other result
|
| ORR | 20% vs 9%+11 vs placeboNCT003904559 other results
| 30%bNCT02668666 |
| Clinical benefit rate | 78.3% vs 74.1%vs AnastrozoleNCT016023809 other results
| 64%bNCT02668666 |
PFS, median
- Fulvestrant
- 4.7 vs 3.8+0.9 vs placeboNCT00390455
17 other results
- 16.6 vs 13.8 NCT01602380
- 4.8 vs 3.5 NCT00253422
- 4.1 vs 3.5 NCT00253422
- 7.5 vs 10 NCT02028507
- 8 NCT01300351
- 4.1 vs 3.8 NCT00390455
- 5.9 vs 3.3 NCT00390455
- 8 vs 10.6 NCT02028507
- 8.3 vs 5.7 NCT02675231
- 5.7 vs 5.7 NCT02675231
- 29.4 NCT03633331
- 5.4 NCT02860000
- 8 NCT03056755
- 5.6 NCT03056755
- 5.6 NCT03056755
- 4.6 NCT01670877
- 5.5 NCT01670877
- Tamoxifen (Soltamox)
- 20.2 vs 15.6vs Endocrine TherapyNCT00601900
2 other results
- 5 NCT03045653
- 9.1 NCT02668666
OS, median
- Fulvestrant
- 29.9 vs 26.4+3.5 vs placeboNCT00390455
10 other results
- 20.1 vs 22.5 NCT00253422
- 20.2 vs 22.5 NCT00253422
- 33.7 vs 32 NCT02028507
- 37.8 vs 38.2 NCT00256698
- 41.3 NCT00075764
- 47.7 NCT00075764
- 35.6 NCT03633331
- 27.3 NCT03056755
- 29 NCT03056755
- 20.7 NCT03056755
- Tamoxifen (Soltamox)
- 47.2 vs 43.9vs Endocrine TherapyNCT00601900
1 other result
- 18.8 NCT02913430
ORR
- Fulvestrant
- 20% vs 9%+11 vs placeboNCT00390455
9 other results
- 13% vs 23% NCT00390455
- 38% vs 17% NCT00390455
- 46.1% vs 44.9% NCT01602380
- 29.9% NCT02860000
- 32.9% vs 13.9% NCT02675231
- 13.9% vs 13.9% NCT02675231
- 19.3% NCT03056755
- 17.5% NCT03056755
- 25.2% NCT03056755
- Tamoxifen (Soltamox)
- 30%bNCT02668666
Clinical benefit rate
- Fulvestrant
- 78.3% vs 74.1%vs AnastrozoleNCT01602380
9 other results
- 55% vs 55.1% NCT00256698
- 70% NCT00075764
- 73% NCT00075764
- 58.2% vs 38% NCT02675231
- 45.6% vs 38% NCT02675231
- 28.9% NCT02860000
- 46.2% NCT03056755
- 35.1% NCT03056755
- 38.3% NCT03056755
- Tamoxifen (Soltamox)
- 64%bNCT02668666
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety
Coverage. Fulvestrant: 11 of 11 rows · Tamoxifen (Soltamox): 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fulvestrant Rows use multiple source trials | Tamoxifen (Soltamox) Rows use multiple source trials |
|---|---|---|
| Clinical Benefit responder rate · % of participants No placebo or comparator arm | 70% (n=345)a,b,c,d NCT00075764 · Phase 3 · registry result, not featured evidence show 1 more dose73% (n=349) NCT00075764 · Phase 3 · registry result, not featured evidence · combination | 64% (n=47)b,c,d NCT02668666 · Phase 2 · registry result, not featured evidence |
| Clinical Benefit event count · % of participants No placebo or comparator arm | 47.7% (n=111)*500 mge,c,f NCT01300351 · Phase 3 · registry result, not featured evidence · converted to % from 53 patients as posted 5 other source trials83.3% (n=54)* NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 45 Participants as posted 30% (n=10)* NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted 38.1% (n=21)* NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to % from 8 Participants as posted 18.5% (n=27) @ 24wk* NCT01142401 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted 21.9% (n=32) @ 24wk* NCT02953860 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted | 50% (n=2) @ 26wk*a,e,c,f NCT02913430 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted show 1 more dose100% (n=2)* NCT02913430 · Phase 1 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted |
| ORR event count · % of participants No placebo or comparator arm | 28.1% (n=57)*500 mgb,c,f,d NCT01300351 · Phase 3 · registry result, not featured evidence · converted to % from 16 patients as posted 3 other source trials33.3% (n=54)* NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 18 Participants as posted 30% (n=10)* NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted 23.8% (n=21)* NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted | 18.6% (n=43) @ 24wk*b,c,f,d NCT00365599 · Phase 2 · registry result, not featured evidence · combination · converted to % from 8 participants as posted |
| ORR responder rate · % of participants No placebo or comparator arm | 29.9% (n=45)c,f,d NCT02860000 · Phase 2 · registry result, not featured evidence · combination 3 other source trials19.3% (n=119) NCT03056755 · Phase 2 · registry result, not featured evidence · combination 17.5% (n=114) NCT03056755 · Phase 2 · registry result, not featured evidence · combination 25.2% (n=115) NCT03056755 · Phase 2 · registry result, not featured evidence · combination | 30% (n=47)c,f,d NCT02668666 · Phase 2 · registry result, not featured evidence |
| Overall Survival time to event · months No placebo or comparator arm | 41.3 monthsa,e,c,d NCT00075764 · Phase 3 · registry result, not featured evidence show 1 more dose47.7 months NCT00075764 · Phase 3 · registry result, not featured evidence · combination | 18.7541 monthse,c,d NCT02913430 · Phase 1 · registry result, not featured evidence · combination |
| PFS time to event · months No placebo or comparator arm | 8 months500 mgb,c,f,d NCT01300351 · Phase 3 · registry result, not featured evidence 7 other source trials29.4 months* NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 895 days as posted 5.4 months NCT02860000 · Phase 2 · registry result, not featured evidence · combination 8 months NCT03056755 · Phase 2 · registry result, not featured evidence · combination 5.6 months NCT03056755 · Phase 2 · registry result, not featured evidence · combination 5.6 months NCT03056755 · Phase 2 · registry result, not featured evidence · combination 4.62 months* NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to months from 20 weeks as posted 5.54 months* NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to months from 24 weeks as posted | 9.13 monthsb,c,f,d NCT02668666 · Phase 2 · registry result, not featured evidence 2 other source trials5 months @ 156wkhigh dose NCT03045653 · Phase 2 · registry result, not featured evidence NA months NCT02913430 · Phase 1 · registry result, not featured evidence · combination |
| Time to Progression time to event · months No placebo or comparator arm | 13.5 monthsa,b,c,d NCT00075764 · Phase 3 · registry result, not featured evidence show 1 more dose15 months NCT00075764 · Phase 3 · registry result, not featured evidence · combination | 10.3 monthsb,c,d NCT00365599 · Phase 2 · registry result, not featured evidence · combination |
| Dropout rate | 89.1%500 mgg NCT01602380 · Phase 3 · combination show 40 more results47.5% NCT05631795 · Phase 4 · registry result, not featured evidence · combination 31.7%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 21.2%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 1.2% NCT02447328 · Phase 4 · registry result, not featured evidence 0%Faslodex + Arimidex NCT00253422 · Phase 3 · registry result, not featured evidence · combination 0%Faslodex + Placebo NCT00253422 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT02028507 · Phase 3 · registry result, not featured evidence · combination —Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence —Anastrozole & Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneArm I Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence n/a: no completion milestoneArm II Anastrozole and Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination 21.6% NCT00390455 · Phase 3 · registry result, not featured evidence 32.4%500 mg NCT01300351 · Phase 3 · registry result, not featured evidence 64.7% NCT00256698 · Phase 3 · registry result, not featured evidence · combination 0% NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 1.1% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 87.5% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 8.2% NCT02860000 · Phase 2 · registry result, not featured evidence · combination 99.2%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 100%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 92.1%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 10.1%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 6.3%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 1.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 1.6% NCT02536742 · Phase 2 · registry result, not featured evidence —Crossover: Neratinib + Fulvestrant NCT01670877 · Phase 2 · registry result, not featured evidence · combination 9.1%Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination 12.5%Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination 3.4%Arm B: Fulvestrant + Bortezomib NCT01142401 · Phase 2 · registry result, not featured evidence · combination —Arm C: Crossover From Arm A at Pro NCT01142401 · Phase 2 · registry result, not featured evidence · combination 0% NCT02953860 · Phase 2 · registry result, not featured evidence · combination 0% NCT01441947 · Phase 2 · registry result, not featured evidence · combination 69.6%500 mg NCT00313170 · Phase 2 · registry result, not featured evidence 76.6%250 mg NCT00313170 · Phase 2 · registry result, not featured evidence 66.7%250 mg + loading dose NCT00313170 · Phase 2 · registry result, not featured evidence · combination | 0%g NCT00601900 · Phase 3 · registry result, not featured evidence · combination show 13 more results0.1% NCT00036270 · Phase 3 · registry result, not featured evidence 0% NCT02668666 · Phase 2 · registry result, not featured evidence 99.2% NCT01124695 · Phase 2 · registry result, not featured evidence 10.7%TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 0%high dose NCT03045653 · Phase 2 · registry result, not featured evidence 63.2% NCT00118157 · Phase 2 · registry result, not featured evidence · combination 11.4% NCT02806544 · Phase 2 · registry result, not featured evidence 0% NCT00365599 · Phase 2 · registry result, not featured evidence · combination 7.7% NCT00952731 · Phase 2 · registry result, not featured evidence · combination — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0% NCT02913430 · Phase 1 · registry result, not featured evidence · combination 17.9% NCT01027416 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —500 mgg NCT01602380 · Phase 3 · combination show 40 more results10% NCT05631795 · Phase 4 · registry result, not featured evidence · combination 3.2%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 1.5%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination — NCT02447328 · Phase 4 · registry result, not featured evidence —Faslodex + Arimidex NCT00253422 · Phase 3 · registry result, not featured evidence · combination —Faslodex + Placebo NCT00253422 · Phase 3 · registry result, not featured evidence 2% NCT02028507 · Phase 3 · registry result, not featured evidence · combination —Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence —Anastrozole & Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination 1.4%Arm I Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence 3.4%Arm II Anastrozole and Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination 11.5% NCT00390455 · Phase 3 · registry result, not featured evidence 0%500 mg NCT01300351 · Phase 3 · registry result, not featured evidence 5% NCT00256698 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination — NCT03633331 · Phase 2 · registry result, not featured evidence · combination — NCT04224272 · Phase 2 · registry result, not featured evidence · combination — NCT02860000 · Phase 2 · registry result, not featured evidence · combination 15.7%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 11.1%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 10.3%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination —150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination — NCT03007979 · Phase 2 · registry result, not featured evidence · combination — NCT02536742 · Phase 2 · registry result, not featured evidence —Crossover: Neratinib + Fulvestrant NCT01670877 · Phase 2 · registry result, not featured evidence · combination —Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination —Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination —Arm B: Fulvestrant + Bortezomib NCT01142401 · Phase 2 · registry result, not featured evidence · combination —Arm C: Crossover From Arm A at Pro NCT01142401 · Phase 2 · registry result, not featured evidence · combination — NCT02953860 · Phase 2 · registry result, not featured evidence · combination — NCT01441947 · Phase 2 · registry result, not featured evidence · combination 0%500 mg NCT00313170 · Phase 2 · registry result, not featured evidence 2.1%250 mg NCT00313170 · Phase 2 · registry result, not featured evidence 3.9%250 mg + loading dose NCT00313170 · Phase 2 · registry result, not featured evidence · combination | —g NCT00601900 · Phase 3 · registry result, not featured evidence · combination show 13 more results— NCT00036270 · Phase 3 · registry result, not featured evidence — NCT02668666 · Phase 2 · registry result, not featured evidence 8.9% NCT01124695 · Phase 2 · registry result, not featured evidence —TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —high dose NCT03045653 · Phase 2 · registry result, not featured evidence 10.5% NCT00118157 · Phase 2 · registry result, not featured evidence · combination — NCT02806544 · Phase 2 · registry result, not featured evidence — NCT00365599 · Phase 2 · registry result, not featured evidence · combination — NCT00952731 · Phase 2 · registry result, not featured evidence · combination — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination — NCT02913430 · Phase 1 · registry result, not featured evidence · combination — NCT01027416 · Phase na · registry result, not featured evidence |
| Serious AEs | 17.1%500 mgg NCT01602380 · Phase 3 · combination show 40 more results25% NCT05631795 · Phase 4 · registry result, not featured evidence · combination 7.9%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 6.6%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 11.1% NCT02447328 · Phase 4 · registry result, not featured evidence 16.9%Faslodex + Arimidex NCT00253422 · Phase 3 · registry result, not featured evidence · combination 13.8%Faslodex + Placebo NCT00253422 · Phase 3 · registry result, not featured evidence 14.1% NCT02028507 · Phase 3 · registry result, not featured evidence · combination 6.2%Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence 13.8%Anastrozole & Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination —Arm I Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence —Arm II Anastrozole and Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination 8.5% NCT00390455 · Phase 3 · registry result, not featured evidence 3.7%500 mg NCT01300351 · Phase 3 · registry result, not featured evidence 15.6% NCT00256698 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 38% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 15.7% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 25% NCT02860000 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 29.1%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 0%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 38.1%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 30.2%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 30%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 19.5%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 30.8%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 27.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 73% NCT02536742 · Phase 2 · registry result, not featured evidence 0%Crossover: Neratinib + Fulvestrant NCT01670877 · Phase 2 · registry result, not featured evidence · combination 18.2%Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination 37.5%Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination 10.5%Arm B: Fulvestrant + Bortezomib NCT01142401 · Phase 2 · registry result, not featured evidence · combination 18.5%Arm C: Crossover From Arm A at Pro NCT01142401 · Phase 2 · registry result, not featured evidence · combination 6.3% NCT02953860 · Phase 2 · registry result, not featured evidence · combination 23.1% NCT01441947 · Phase 2 · registry result, not featured evidence · combination 8.7%500 mg NCT00313170 · Phase 2 · registry result, not featured evidence 8.5%250 mg NCT00313170 · Phase 2 · registry result, not featured evidence 18%250 mg + loading dose NCT00313170 · Phase 2 · registry result, not featured evidence · combination | 28.7%g NCT00601900 · Phase 3 · registry result, not featured evidence · combination show 13 more results17.1% NCT00036270 · Phase 3 · registry result, not featured evidence 32.7% NCT02668666 · Phase 2 · registry result, not featured evidence 24.6% NCT01124695 · Phase 2 · registry result, not featured evidence —TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 3.6%TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 0%high dose NCT03045653 · Phase 2 · registry result, not featured evidence 100% NCT00118157 · Phase 2 · registry result, not featured evidence · combination 0% NCT02806544 · Phase 2 · registry result, not featured evidence 9.3% NCT00365599 · Phase 2 · registry result, not featured evidence · combination 0% NCT00952731 · Phase 2 · registry result, not featured evidence · combination 0% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0% NCT02913430 · Phase 1 · registry result, not featured evidence · combination 0% NCT01027416 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | show 33 more resultshyperglycaemia 90% stomatitis 37.5% diarrhoea 35% NCT05631795 · Phase 4 · registry result, not featured evidence · combination diarrhoea 28.6% anaemia 22.2% fatigue 20.6% NCT04707196 · Phase 4 · registry result, not featured evidence · combination diarrhoea 29.9% neutropenia 24.8% anaemia 23.4% NCT04707196 · Phase 4 · registry result, not featured evidence · combination myalgia 12.3% nausea 12.3% back pain 11.1% NCT02447328 · Phase 4 · registry result, not featured evidence lethargy 64.5% arthralgia 42% hot flush 37.2% NCT00253422 · Phase 3 · registry result, not featured evidence · combination lethargy 64.4% vomiting 44.9% arthralgia 43.6% NCT00253422 · Phase 3 · registry result, not featured evidence neutrophil count decreased 63.1% fatigue 51% hypertension 36.9% NCT02028507 · Phase 3 · registry result, not featured evidence · combination fatigue (asthenia, lethargy, malaise) 60.2% hot flashes/flushes 45.7% pain - joint 45.1% NCT00075764 · Phase 3 · registry result, not featured evidence fatigue (asthenia, lethargy, malaise) 63.2% hot flashes/flushes 54.3% pain - joint 44% NCT00075764 · Phase 3 · registry result, not featured evidence · combination diarrhea 62.4% (placebo 21.9%) fatigue 55.3% (placebo 53.3%) rash acneiform 41.1% (placebo 4.4%) NCT00390455 · Phase 3 · registry result, not featured evidence 500 mg injection site reaction 11% pyrexia 10.1% fatigue 8.3% NCT01300351 · Phase 3 · registry result, not featured evidence arthralgia 11.7% fatigue 10.5% nausea 9% NCT00256698 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 92.4% white blood cell decreased 87% fatigue 84.8% NCT03633331 · Phase 2 · registry result, not featured evidence · combination diarrhoea 92.2% nausea 52.9% stomatitis 41.2% NCT04224272 · Phase 2 · registry result, not featured evidence · combination fatigue 83.3% anemia 62.5% neutrophil count decreased 60.4% NCT02860000 · Phase 2 · registry result, not featured evidence · combination diarrhoea 64.6% hyperglycaemia 59.8% nausea 46.5% NCT03056755 · Phase 2 · registry result, not featured evidence · combination asthenia 100% blood creatinine increased 100% diarrhoea 100% NCT03056755 · Phase 2 · registry result, not featured evidence · combination diarrhoea 68.3% hyperglycaemia 64.3% nausea 54% NCT03056755 · Phase 2 · registry result, not featured evidence · combination hyperglycaemia 67.5% diarrhoea 54% nausea 40.5% NCT03056755 · Phase 2 · registry result, not featured evidence · combination diarrhoea 70% hyperglycaemia 60% fatigue 50% NCT03056755 · Phase 2 · registry result, not featured evidence · combination 150 mg + 8 mg/kg diarrhoea 77.9% fatigue 53.2% nausea 41.6% NCT02675231 · Phase 2 · registry result, not featured evidence · combination 150 mg + 8 mg/kg + 500 mg diarrhoea 79.5% fatigue 57.7% nausea 48.7% NCT02675231 · Phase 2 · registry result, not featured evidence · combination white blood cell count decreased 96.3% neutrophil count decreased 87% anemia 79.6% NCT03007979 · Phase 2 · registry result, not featured evidence · combination vomiting 60% anorexia 40% constipation 40% NCT01670877 · Phase 2 · registry result, not featured evidence · combination diarrhea 81.8% anorexia 63.6% aspartate aminotransferase increased 45.5% NCT01670877 · Phase 2 · registry result, not featured evidence · combination diarrhea 91.7% fatigue 50% nausea 50% NCT01670877 · Phase 2 · registry result, not featured evidence · combination hemoglobin - low 61.4% thrombocytopenia 61.4% nausea 59.6% NCT01142401 · Phase 2 · registry result, not featured evidence · combination hemoglobin - low 55.6% thrombocytopenia 55.6% diarrhea 51.9% NCT01142401 · Phase 2 · registry result, not featured evidence · combination fatigue 53.1% nausea 50% achiness 43.8% NCT02953860 · Phase 2 · registry result, not featured evidence · combination fatigue 76.9% anorexia 61.5% pain 53.8% NCT01441947 · Phase 2 · registry result, not featured evidence · combination 500 mg back pain 15.2% fatigue 15.2% nausea 15.2% NCT00313170 · Phase 2 · registry result, not featured evidence 250 mg nausea 25.5% hot flush 19.1% cough 12.8% NCT00313170 · Phase 2 · registry result, not featured evidence 250 mg + loading dose fatigue 22% nausea 18% back pain 16% NCT00313170 · Phase 2 · registry result, not featured evidence · combination | g arthralgia 70.3% hypertension 59% proteinuria 47.7% NCT00601900 · Phase 3 · registry result, not featured evidence · combination show 11 more resultshot flush 31.3% arthralgia 23.8% fatigue 16.4% NCT00036270 · Phase 3 · registry result, not featured evidence neutrophil count decreased 71.4% fatigue 65.3% white blood cell decreased 65.3% NCT02668666 · Phase 2 · registry result, not featured evidence fatigue 14.8% back pain 13.9% nausea 11.5% NCT01124695 · Phase 2 · registry result, not featured evidence nausea 100% NCT02988986 · Phase 2 · registry result, not featured evidence · combination anemia 36.8% nausea 36.8% anorexia 31.6% NCT00118157 · Phase 2 · registry result, not featured evidence · combination fatigue - grade 2 18.6% nausea - grade 2 18.6% anorexia/weight loss - grade 2 16.3% NCT00365599 · Phase 2 · registry result, not featured evidence · combination hot flashes 58.3% pain 41.7% pain: breast 41.7% NCT00952731 · Phase 2 · registry result, not featured evidence · combination arthralgia 33.3% back pain 33.3% headache 33.3% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination blood and lymphatic system disorders - other 50% hypertension 50% neutrophil count decreased 50% NCT02913430 · Phase 1 · registry result, not featured evidence · combination headache 32.1% (placebo 0%) night sweats 32.1% (placebo 0%) irritability 28.6% (placebo 0%) NCT01027416 · Phase na · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 3.
- cPopulation comparability has not been reviewed for both studies.
- dThe assessment timepoint is not available for both results.
- eTrial phases differ: Phase 1 versus Phase 3.
- fTreatment context has not been resolved for both arms.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fulvestrant
show 5 more results
show 6 more results
show 3 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 60 further endpoints in the CSV export.
Tamoxifen (Soltamox)
show 1 more result
show 1 more result
Breast Cancer
Shared mechanism: Estrogen receptor · full Breast Cancer pipeline
Fulvestrant · Faslodex
Marketed by AstraZeneca
NCT00635713 · Phase 3 · completed
The trial randomized an estimated 588 participants and used double blinding to compare two active treatment groups: fulvestrant 125 mg plus anastrozole versus fulvestrant 250 mg plus anastrozole. Its primary endpoint was time to tumor progression, a clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
ClinicalTrials.gov records both arms as fulvestrant plus anastrozole. The published North American Trial 0021 (Osborne 2002) randomized fulvestrant 250 mg monthly against anastrozole 1 mg daily, double-blind and double-dummy.
Next expected readout: December 2026 · NCT07163481 (registry estimate)
Reported efficacy
Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59) (met)
Result source: NCT01602380
Tamoxifen (Soltamox)
Marketed by Mayne Pharma and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04174352 (registry estimate)
Reported efficacy
Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) (mixed)
Result source: NCT00066690
Results for Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Fulvestrant: 11 of 11 rows · Tamoxifen (Soltamox): 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fulvestrant Rows use multiple source trials | Tamoxifen (Soltamox) Rows use multiple source trials |
|---|---|---|
| Clinical Benefit responder rate · % of participants No placebo or comparator arm | 70% (n=345)a,b,c,d NCT00075764 · Phase 3 · registry result, not featured evidence show 1 more dose73% (n=349) NCT00075764 · Phase 3 · registry result, not featured evidence · combination | 64% (n=47)b,c,d NCT02668666 · Phase 2 · registry result, not featured evidence |
| ORR event count · % of participants No placebo or comparator arm | 28.1% (n=57)*500 mgb,c,e,d NCT01300351 · Phase 3 · registry result, not featured evidence · converted to % from 16 patients as posted 5 other source trials0% (n=3)* NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 3.7% (n=27)* NCT03620643 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 33.3% (n=54)* NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 18 Participants as posted 30% (n=10)* NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted 23.8% (n=21)* NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted | 18.6% (n=43) @ 24wk*b,c,e,d NCT00365599 · Phase 2 · registry result, not featured evidence · combination · converted to % from 8 participants as posted |
| ORR responder rate · % of participants No placebo or comparator arm | 29.9% (n=45)c,e,d NCT02860000 · Phase 2 · registry result, not featured evidence · combination 3 other source trials19.3% (n=119) NCT03056755 · Phase 2 · registry result, not featured evidence · combination 17.5% (n=114) NCT03056755 · Phase 2 · registry result, not featured evidence · combination 25.2% (n=115) NCT03056755 · Phase 2 · registry result, not featured evidence · combination | 30% (n=47)c,e,d NCT02668666 · Phase 2 · registry result, not featured evidence |
| Overall Survival time to event · months | 20.2 vs 22.5 Exemestane monthsa,c,d NCT00253422 · Phase 3 · registry result, not featured evidence · combination show 1 more dose20.1 vs 22.5 Exemestane months NCT00253422 · Phase 3 · registry result, not featured evidence | 47.2 vs 43.9 Endocrine Therapy monthsc,d NCT00601900 · Phase 3 · registry result, not featured evidence · combination 4 other source trialsNA vs NA Anastrozole months NCT00295646 · Phase 3 · registry result, not featured evidence NA vs NA Anastrozole months NCT00295646 · Phase 3 · registry result, not featured evidence NA vs NA Anastrozole months NCT00295646 · Phase 3 · registry result, not featured evidence · combination NA vs NA Anastrozole months NCT00295646 · Phase 3 · registry result, not featured evidence · combination |
| PFS time to event · months | 16.6 vs 13.8 Anastrozole months500 mgc,d NCT01602380 · Phase 3 · combination 9 other source trials4.1 vs 3.5 Exemestane months NCT00253422 · Phase 3 · registry result, not featured evidence · combination 4.8 vs 3.5 Exemestane months NCT00253422 · Phase 3 · registry result, not featured evidence 7.5 vs 9.4 Capecitabine months NCT02028507 · Phase 3 · registry result, not featured evidence · combination 8 vs 10.6 Capecitabine months NCT02028507 · Phase 3 · registry result, not featured evidence · combination 4.7 vs 3.8 placebo months NCT00390455 · Phase 3 · registry result, not featured evidence 4.1 vs 3.8 placebo months NCT00390455 · Phase 3 · registry result, not featured evidence 5.9 vs 3.3 placebo months NCT00390455 · Phase 3 · registry result, not featured evidence 5.7 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 8.3 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination | 20.2 vs 15.6 Endocrine Therapy monthsc,d NCT00601900 · Phase 3 · registry result, not featured evidence · combination |
| PFS time to event · months No placebo or comparator arm | 8 months500 mgb,c,e,d NCT01300351 · Phase 3 · registry result, not featured evidence 9 other source trials29.4 months* NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 895 days as posted 5.4 months NCT02860000 · Phase 2 · registry result, not featured evidence · combination 8 months NCT03056755 · Phase 2 · registry result, not featured evidence · combination 5.6 months NCT03056755 · Phase 2 · registry result, not featured evidence · combination 5.6 months NCT03056755 · Phase 2 · registry result, not featured evidence · combination 1.8 months NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy 1.8 months NCT03620643 · Phase 2 · registry result, not featured evidence · combination 4.62 months* NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to months from 20 weeks as posted 5.54 months* NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to months from 24 weeks as posted | 9.13 monthsb,c,e,d NCT02668666 · Phase 2 · registry result, not featured evidence 1 other source trial5 months @ 156wkhigh dose NCT03045653 · Phase 2 · registry result, not featured evidence |
| Time to Progression time to event · months No placebo or comparator arm | 13.5 monthsa,b,c,d NCT00075764 · Phase 3 · registry result, not featured evidence show 1 more dose15 months NCT00075764 · Phase 3 · registry result, not featured evidence · combination | 10.3 monthsb,c,d NCT00365599 · Phase 2 · registry result, not featured evidence · combination |
| Dropout rate | 89.1%500 mgf NCT01602380 · Phase 3 · combination show 39 more results47.5% NCT05631795 · Phase 4 · registry result, not featured evidence · combination 31.7%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 21.2%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 1.2% NCT02447328 · Phase 4 · registry result, not featured evidence 0%Faslodex + Arimidex NCT00253422 · Phase 3 · registry result, not featured evidence · combination 0%Faslodex + Placebo NCT00253422 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT02028507 · Phase 3 · registry result, not featured evidence · combination —Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence —Anastrozole & Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneArm I Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence n/a: no completion milestoneArm II Anastrozole and Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination 21.6% NCT00390455 · Phase 3 · registry result, not featured evidence 32.4%500 mg NCT01300351 · Phase 3 · registry result, not featured evidence 64.7% NCT00256698 · Phase 3 · registry result, not featured evidence · combination 0% NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 1.1% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 87.5% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 8.2% NCT02860000 · Phase 2 · registry result, not featured evidence · combination 99.2%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 100%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 92.1%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 0%Crizotinib Oral Capsule [Xalkori] NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy 0%Crizotinib Oral Capsule [Xalkori] NCT03620643 · Phase 2 · registry result, not featured evidence · combination 10.1%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 6.3%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 1.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 1.6% NCT02536742 · Phase 2 · registry result, not featured evidence —Crossover: Neratinib + Fulvestrant NCT01670877 · Phase 2 · registry result, not featured evidence · combination 9.1%Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination 12.5%Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination 3.4%Arm B: Fulvestrant + Bortezomib NCT01142401 · Phase 2 · registry result, not featured evidence · combination —Arm C: Crossover From Arm A at Pro NCT01142401 · Phase 2 · registry result, not featured evidence · combination 0% NCT02953860 · Phase 2 · registry result, not featured evidence · combination 0% NCT01441947 · Phase 2 · registry result, not featured evidence · combination | 29.6%E+OFSf NCT00066690 · Phase 3 · registry result, not featured evidence · combination show 17 more results26.7%T+OFS NCT00066690 · Phase 3 · registry result, not featured evidence · combination 0% NCT00601900 · Phase 3 · registry result, not featured evidence · combination 10%TC (Tamoxifen Control) NCT00295646 · Phase 3 · registry result, not featured evidence 9.1%TZ (Tamoxifen+Zoledronate) NCT00295646 · Phase 3 · registry result, not featured evidence · combination 0% NCT02668666 · Phase 2 · registry result, not featured evidence 99.2% NCT01124695 · Phase 2 · registry result, not featured evidence 3.2%Exemestane NCT01831076 · Phase 2 · registry result, not featured evidence 20%Exemestane Plus Tamoxifen NCT01831076 · Phase 2 · registry result, not featured evidence · combination 10.7%TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 0%high dose NCT03045653 · Phase 2 · registry result, not featured evidence 0% NCT01614210 · Phase 2 · registry result, not featured evidence 63.2% NCT00118157 · Phase 2 · registry result, not featured evidence · combination 11.4% NCT02806544 · Phase 2 · registry result, not featured evidence 0% NCT00365599 · Phase 2 · registry result, not featured evidence · combination 7.7% NCT00952731 · Phase 2 · registry result, not featured evidence · combination 17.6% NCT00499083 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —500 mgf NCT01602380 · Phase 3 · combination show 39 more results10% NCT05631795 · Phase 4 · registry result, not featured evidence · combination 3.2%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 1.5%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination — NCT02447328 · Phase 4 · registry result, not featured evidence —Faslodex + Arimidex NCT00253422 · Phase 3 · registry result, not featured evidence · combination —Faslodex + Placebo NCT00253422 · Phase 3 · registry result, not featured evidence 2% NCT02028507 · Phase 3 · registry result, not featured evidence · combination —Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence —Anastrozole & Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination 1.4%Arm I Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence 3.4%Arm II Anastrozole and Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination 11.5% NCT00390455 · Phase 3 · registry result, not featured evidence 0%500 mg NCT01300351 · Phase 3 · registry result, not featured evidence 5% NCT00256698 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination — NCT03633331 · Phase 2 · registry result, not featured evidence · combination — NCT04224272 · Phase 2 · registry result, not featured evidence · combination — NCT02860000 · Phase 2 · registry result, not featured evidence · combination 15.7%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 11.1%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 10.3%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Crizotinib Oral Capsule [Xalkori] NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy —Crizotinib Oral Capsule [Xalkori] NCT03620643 · Phase 2 · registry result, not featured evidence · combination —150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination —150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination — NCT03007979 · Phase 2 · registry result, not featured evidence · combination — NCT02536742 · Phase 2 · registry result, not featured evidence —Crossover: Neratinib + Fulvestrant NCT01670877 · Phase 2 · registry result, not featured evidence · combination —Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination —Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination —Arm B: Fulvestrant + Bortezomib NCT01142401 · Phase 2 · registry result, not featured evidence · combination —Arm C: Crossover From Arm A at Pro NCT01142401 · Phase 2 · registry result, not featured evidence · combination — NCT02953860 · Phase 2 · registry result, not featured evidence · combination — NCT01441947 · Phase 2 · registry result, not featured evidence · combination | 13.2%E+OFSf NCT00066690 · Phase 3 · registry result, not featured evidence · combination show 17 more results6.8%T+OFS NCT00066690 · Phase 3 · registry result, not featured evidence · combination — NCT00601900 · Phase 3 · registry result, not featured evidence · combination —TC (Tamoxifen Control) NCT00295646 · Phase 3 · registry result, not featured evidence —TZ (Tamoxifen+Zoledronate) NCT00295646 · Phase 3 · registry result, not featured evidence · combination — NCT02668666 · Phase 2 · registry result, not featured evidence 8.9% NCT01124695 · Phase 2 · registry result, not featured evidence —Exemestane NCT01831076 · Phase 2 · registry result, not featured evidence —Exemestane Plus Tamoxifen NCT01831076 · Phase 2 · registry result, not featured evidence · combination —TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination —high dose NCT03045653 · Phase 2 · registry result, not featured evidence — NCT01614210 · Phase 2 · registry result, not featured evidence 10.5% NCT00118157 · Phase 2 · registry result, not featured evidence · combination — NCT02806544 · Phase 2 · registry result, not featured evidence — NCT00365599 · Phase 2 · registry result, not featured evidence · combination — NCT00952731 · Phase 2 · registry result, not featured evidence · combination — NCT00499083 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 17.1%500 mgf NCT01602380 · Phase 3 · combination show 39 more results25% NCT05631795 · Phase 4 · registry result, not featured evidence · combination 7.9%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 6.6%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 11.1% NCT02447328 · Phase 4 · registry result, not featured evidence 16.9%Faslodex + Arimidex NCT00253422 · Phase 3 · registry result, not featured evidence · combination 13.8%Faslodex + Placebo NCT00253422 · Phase 3 · registry result, not featured evidence 14.1% NCT02028507 · Phase 3 · registry result, not featured evidence · combination 6.2%Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence 13.8%Anastrozole & Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination —Arm I Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence —Arm II Anastrozole and Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination 8.5% NCT00390455 · Phase 3 · registry result, not featured evidence 3.7%500 mg NCT01300351 · Phase 3 · registry result, not featured evidence 15.6% NCT00256698 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 38% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 15.7% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 25% NCT02860000 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 29.1%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 0%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 38.1%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 30.2%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 30%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 66.7%Crizotinib Oral Capsule [Xalkori] NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy 18.5%Crizotinib Oral Capsule [Xalkori] NCT03620643 · Phase 2 · registry result, not featured evidence · combination 19.5%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 30.8%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 27.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 73% NCT02536742 · Phase 2 · registry result, not featured evidence 0%Crossover: Neratinib + Fulvestrant NCT01670877 · Phase 2 · registry result, not featured evidence · combination 18.2%Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination 37.5%Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination 10.5%Arm B: Fulvestrant + Bortezomib NCT01142401 · Phase 2 · registry result, not featured evidence · combination 18.5%Arm C: Crossover From Arm A at Pro NCT01142401 · Phase 2 · registry result, not featured evidence · combination 6.3% NCT02953860 · Phase 2 · registry result, not featured evidence · combination 23.1% NCT01441947 · Phase 2 · registry result, not featured evidence · combination | 37.5%E+OFSf NCT00066690 · Phase 3 · registry result, not featured evidence · combination show 17 more results37.2%T+OFS NCT00066690 · Phase 3 · registry result, not featured evidence · combination 28.7% NCT00601900 · Phase 3 · registry result, not featured evidence · combination 20.7%TC (Tamoxifen Control) NCT00295646 · Phase 3 · registry result, not featured evidence 22.9%TZ (Tamoxifen+Zoledronate) NCT00295646 · Phase 3 · registry result, not featured evidence · combination 32.7% NCT02668666 · Phase 2 · registry result, not featured evidence 24.6% NCT01124695 · Phase 2 · registry result, not featured evidence 0%Exemestane NCT01831076 · Phase 2 · registry result, not featured evidence 0%Exemestane Plus Tamoxifen NCT01831076 · Phase 2 · registry result, not featured evidence · combination —TAK-228 Plus Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 3.6%TAK-228 and Tamoxifen NCT02988986 · Phase 2 · registry result, not featured evidence · combination 0%high dose NCT03045653 · Phase 2 · registry result, not featured evidence 1.9% NCT01614210 · Phase 2 · registry result, not featured evidence 100% NCT00118157 · Phase 2 · registry result, not featured evidence · combination 0% NCT02806544 · Phase 2 · registry result, not featured evidence 9.3% NCT00365599 · Phase 2 · registry result, not featured evidence · combination 0% NCT00952731 · Phase 2 · registry result, not featured evidence · combination 33.3% NCT00499083 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 32 more resultshyperglycaemia 90% stomatitis 37.5% diarrhoea 35% NCT05631795 · Phase 4 · registry result, not featured evidence · combination diarrhoea 28.6% anaemia 22.2% fatigue 20.6% NCT04707196 · Phase 4 · registry result, not featured evidence · combination diarrhoea 29.9% neutropenia 24.8% anaemia 23.4% NCT04707196 · Phase 4 · registry result, not featured evidence · combination myalgia 12.3% nausea 12.3% back pain 11.1% NCT02447328 · Phase 4 · registry result, not featured evidence lethargy 64.5% arthralgia 42% hot flush 37.2% NCT00253422 · Phase 3 · registry result, not featured evidence · combination lethargy 64.4% vomiting 44.9% arthralgia 43.6% NCT00253422 · Phase 3 · registry result, not featured evidence neutrophil count decreased 63.1% fatigue 51% hypertension 36.9% NCT02028507 · Phase 3 · registry result, not featured evidence · combination fatigue (asthenia, lethargy, malaise) 60.2% hot flashes/flushes 45.7% pain - joint 45.1% NCT00075764 · Phase 3 · registry result, not featured evidence fatigue (asthenia, lethargy, malaise) 63.2% hot flashes/flushes 54.3% pain - joint 44% NCT00075764 · Phase 3 · registry result, not featured evidence · combination diarrhea 62.4% (placebo 21.9%) fatigue 55.3% (placebo 53.3%) rash acneiform 41.1% (placebo 4.4%) NCT00390455 · Phase 3 · registry result, not featured evidence 500 mg injection site reaction 11% pyrexia 10.1% fatigue 8.3% NCT01300351 · Phase 3 · registry result, not featured evidence arthralgia 11.7% fatigue 10.5% nausea 9% NCT00256698 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 92.4% white blood cell decreased 87% fatigue 84.8% NCT03633331 · Phase 2 · registry result, not featured evidence · combination diarrhoea 92.2% nausea 52.9% stomatitis 41.2% NCT04224272 · Phase 2 · registry result, not featured evidence · combination fatigue 83.3% anemia 62.5% neutrophil count decreased 60.4% NCT02860000 · Phase 2 · registry result, not featured evidence · combination diarrhoea 64.6% hyperglycaemia 59.8% nausea 46.5% NCT03056755 · Phase 2 · registry result, not featured evidence · combination asthenia 100% blood creatinine increased 100% diarrhoea 100% NCT03056755 · Phase 2 · registry result, not featured evidence · combination diarrhoea 68.3% hyperglycaemia 64.3% nausea 54% NCT03056755 · Phase 2 · registry result, not featured evidence · combination hyperglycaemia 67.5% diarrhoea 54% nausea 40.5% NCT03056755 · Phase 2 · registry result, not featured evidence · combination diarrhoea 70% hyperglycaemia 60% fatigue 50% NCT03056755 · Phase 2 · registry result, not featured evidence · combination alanine aminotransferase increased 66.7% aspartate aminotransferase increased 66.7% dyspnea 50% NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy aspartate aminotransferase increased 74.1% nausea 74.1% alanine aminotransferase increased 63% NCT03620643 · Phase 2 · registry result, not featured evidence · combination 150 mg + 8 mg/kg diarrhoea 77.9% fatigue 53.2% nausea 41.6% NCT02675231 · Phase 2 · registry result, not featured evidence · combination 150 mg + 8 mg/kg + 500 mg diarrhoea 79.5% fatigue 57.7% nausea 48.7% NCT02675231 · Phase 2 · registry result, not featured evidence · combination white blood cell count decreased 96.3% neutrophil count decreased 87% anemia 79.6% NCT03007979 · Phase 2 · registry result, not featured evidence · combination vomiting 60% anorexia 40% constipation 40% NCT01670877 · Phase 2 · registry result, not featured evidence · combination diarrhea 81.8% anorexia 63.6% aspartate aminotransferase increased 45.5% NCT01670877 · Phase 2 · registry result, not featured evidence · combination diarrhea 91.7% fatigue 50% nausea 50% NCT01670877 · Phase 2 · registry result, not featured evidence · combination hemoglobin - low 61.4% thrombocytopenia 61.4% nausea 59.6% NCT01142401 · Phase 2 · registry result, not featured evidence · combination hemoglobin - low 55.6% thrombocytopenia 55.6% diarrhea 51.9% NCT01142401 · Phase 2 · registry result, not featured evidence · combination fatigue 53.1% nausea 50% achiness 43.8% NCT02953860 · Phase 2 · registry result, not featured evidence · combination fatigue 76.9% anorexia 61.5% pain 53.8% NCT01441947 · Phase 2 · registry result, not featured evidence · combination | f hot flashes/flushes 81.9% pain - joint 77.7% fatigue (asthenia, lethargy, malaise) 59% NCT00066690 · Phase 3 · registry result, not featured evidence · combination show 13 more resultshot flashes/flushes 80% pain - joint 69.5% sweating (diaphoresis) 61.7% NCT00066690 · Phase 3 · registry result, not featured evidence · combination arthralgia 70.3% hypertension 59% proteinuria 47.7% NCT00601900 · Phase 3 · registry result, not featured evidence · combination other/minor (not categorized) 24% bone pain 20.9% fatigue 15.6% NCT00295646 · Phase 3 · registry result, not featured evidence bone pain 29.3% other/minor (not categorized) 24.9% fatigue 18.2% NCT00295646 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 71.4% fatigue 65.3% white blood cell decreased 65.3% NCT02668666 · Phase 2 · registry result, not featured evidence fatigue 14.8% back pain 13.9% nausea 11.5% NCT01124695 · Phase 2 · registry result, not featured evidence nausea 100% NCT02988986 · Phase 2 · registry result, not featured evidence · combination hot flashes 36.5% nausea 21.2% fatigue 9.6% NCT01614210 · Phase 2 · registry result, not featured evidence anemia 36.8% nausea 36.8% anorexia 31.6% NCT00118157 · Phase 2 · registry result, not featured evidence · combination fatigue - grade 2 18.6% nausea - grade 2 18.6% anorexia/weight loss - grade 2 16.3% NCT00365599 · Phase 2 · registry result, not featured evidence · combination hot flashes 58.3% pain 41.7% pain: breast 41.7% NCT00952731 · Phase 2 · registry result, not featured evidence · combination bone pain 33.3% hypokalemia 33.3% mucositis oral 33.3% NCT00499083 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 3.
- cPopulation comparability has not been reviewed for both studies.
- dThe assessment timepoint is not available for both results.
- eTreatment context has not been resolved for both arms.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fulvestrant
show 5 more results
show 6 more results
show 3 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 61 further endpoints in the CSV export.
Tamoxifen (Soltamox)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 3 more results
show 2 more results
show 2 more results
+ 3 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fulvestrant's landscape · Tamoxifen (Soltamox)'s landscape